Abstract
Matrine is an alkaloid extracted from a Chinese herb Sophora flavescens Ait, which has shown chemopreventive potential against various cancers. In this study, we evaluated the anticancer efficacy of a novel derivative of matrine, (6aS, 10S, 11aR, 11bR, 11cS)-10- methylamino-dodecahydro- 3a,7a-diazabenzo (de) (MASM), against human hepatocellular carcinoma (HCC) cells and their corresponding sphere cells in vitro and in vivo. Human HCC cell lines (Hep3B and Huh7) were treated with MASM. Cell proliferation was assessed using CCK8 and colony assays; cell apoptosis and cell cycle distributions were examined with flow cytometry. The expression of cell markers and signaling molecules was detected using Western blot and qRT-PCR analyses. A sphere culture technique was used to enrich cancer stem cells (CSC) in Hep3B and Huh7 cells. The in vivo antitumor efficacy of MASM was evaluated in Huh7 cell xenograft model in BALB/c nude mice, which were administered MASM (10 mg·kg−1·d−1, ig) for 3 weeks. After the treatment was completed, tumor were excised and weighed. A portion of tumor tissue was enzymatically dissociated to obtain a single cell suspension for the spheroid formation assays. MASM (2, 10, 20 μmol/L) dose-dependently inhibited the proliferation of HCC cells, and induced apoptosis, which correlated with a reduction in Bcl-2 expression and an increase in PARP cleavage. MASM also induced cell cycle arrest in G0/G1 phase, which was accompanied by increased p27 and decreased Cyclin D1 expression. Interestingly, MASM (2, 10, and 20 μmol/L) drastically reduced the EpCAM+/CD133+ cell numbers, suppressed the sphere formation, inhibited the expression of stem cell marker genes and promoted the expression of mature hepatocyte markers in the Hep3B and Huh7 spheroids. Additionally, MASM dose-dependently suppressed the PI3K/AKT/mTOR and AKT/GSK3β/β-catenin signaling pathways in Hep3B and Huh7 cells. In Huh7 xenograft bearing nude mice, MASM administration significantly inhibited Huh7 xenograft tumor growth and markedly reduced the number of surviving cancer stem-like cells in the tumors. MASM administration also reduced the expression of stem cell markers while increasing the expression of mature hepatocyte markers in the tumor tissues. The novel derivative of matrine, MASM, markedly suppresses HCC tumor growth through multiple mechanisms, and it may be a promising candidate drug for the treatment of hepatocellular carcinoma.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ferrin G, Aguilar-Melero P, Rodriguez-Peralvarez M, Montero-Alvarez JL, de la Mata M . Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepatic Med 2015; 7: 1–10.
El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158–66.
Davila JA, Duan Z, McGlynn KA, El-Serag HB . Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol 2012; 46: 71–7.
Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P . Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008; 15: 1008–14.
Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–11.
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542–56.
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484–97.
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012–24.
Xu X, Liu RF, Zhang X, Huang LY, Chen F, Fei QL, et al. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther 2012; 11: 629–38.
Huang WC, Chan CC, Wu SJ, Chen LC, Shen JJ, Kuo ML, et al. Matrine attenuates allergic airway inflammation and eosinophil infiltration by suppressing eotaxin and Th2 cytokine production in asthmatic mice. J Ethnopharmacol 2014; 151: 470–7.
Long Y, Lin XT, Zeng KL, Zhang L . Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobil Pancreatic Dis Int 2004; 3: 69–72.
Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin 2001; 22: 183–6.
Li X, Chu W, Liu J, Xue X, Lu Y, Shan H, et al. Antiarrhythmic properties of long-term treatment with matrine in arrhythmic rat induced by coronary ligation. Biol Pharm Bull 2009; 32: 1521–6.
Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L . Matrine induces cell energy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull 2010; 33: 40–6.
Yong J, Wu X, Lu C . Anticancer advances of matrine and its derivatives. Curr Pharm Des 2015; 21: 3673–80.
Zhang L, Liu W, Zhang R, Wang Z, Shen Z, Chen X, et al. Pharmacokinetic study of matrine, oxymatrine and oxysophocarpine in rat plasma after oral administration of Sophora flavescens Ait. extract by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2008; 47: 892–8.
Hu H, Wang S, Zhang C, Wang L, Ding L, Zhang J, et al. Synthesis and in vitro inhibitory activity of matrine derivatives towards pro-inflammatory cytokines. Bioorg Med Chem Lett 2010; 20: 7537–9.
Xu J, Qi Y, Xu WH, Liu Y, Qiu L, Wang KQ, et al. Matrine derivate MASM suppresses LPS-induced phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int Immunopharmacol 2016; 36: 59–66.
Xu WH, Hu HG, Tian Y, Wang SZ, Li J, Li JZ, et al. Bioactive compound reveals a novel function for ribosomal protein S5 in hepatic stellate cell activation and hepatic fibrosis. Hepatology 2014; 60: 648–60.
Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837–47.
Bock AS, Leigh ND, Bryda EC . Effect of Gsk3 inhibitor CHIR99021 on aneuploidy levels in rat embryonic stem cells. In Vitro Cell Dev Biol Anim 2014; 50: 572–9.
Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769–76.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785–9.
Zhang Z, Wang X, Wu W, Wang J, Wang Y, Wu X, et al. Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother Res 2012; 26: 932–7.
Chang C, Liu SP, Fang CH, He RS, Wang Z, Zhu YQ, et al. Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism. Oncol lett 2013; 6: 699–704.
Zhang J, Li Y, Chen X, Liu T, Chen Y, He W, et al. Autophagy is involved in anticancer effects of matrine on SGC-7901 human gastric cancer cells. Oncol Rep 2011; 26: 115–24.
Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, et al. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology 2009; 59: 191–200.
Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, et al. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One 2012; 7: e46853.
Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, et al. Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010; 16: 4281–90.
Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, et al. Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 2012; 30: 631–41.
de Murcia G, Menissier de Murcia J . Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994; 19: 172–6.
Liu LF . DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75.
Matsuda Y, Wakai T, Kubota M, Takamura M, Yamagiwa S, Aoyagi Y, et al. Clinical significance of cell cycle inhibitors in hepatocellular carcinoma. Med Mol Morphol 2013; 46: 185–92.
Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010; 16: 2580–90.
Song HK, Kim J, Lee JS, Nho KJ, Jeong HC, Kim J, et al. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway. PloS One 2015; 10: e0122251.
Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587–97.
Li GY, Jung KH, Lee H, Son MK, Seo J, Hong SW, et al. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. Cancer Lett 2013; 329: 59–67.
Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN . Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008; 26: 3027–36.
Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287–95.
Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature 2005; 434: 843–50.
Acknowledgements
This project was supported by grants from the National Natural Science Foundation of China (No 81270508) and the National Major Special Science and Technology Project (No 2012ZX09103101-043). The funding agency had no role in the actual experimental design, analysis, or writing of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Liu, Y., Qi, Y., Bai, Zh. et al. A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways. Acta Pharmacol Sin 38, 120–132 (2017). https://doi.org/10.1038/aps.2016.104
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.104
Keywords
This article is cited by
-
Role of CD133 antibody-conjugated nanocarrier in enhancing the targetability of hepatocellular carcinoma stem cells
Scientific Reports (2025)
-
Single-cell and spatial transcriptome-based metabolism-immunity interaction network and therapeutic target discovery of matrine in cervical cancer
Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
-
Preventive effect of matrine on clostridium perfringens type A-induced diarrhoea in piglets
Veterinary Research Communications (2025)
-
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery
Molecular Cancer (2024)
-
Matrine inhibits invasion and migration of gallbladder cancer via regulating the PI3K/AKT signaling pathway
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
